![](/rp/kFAqShRrnkQMbH6NYLBYoJ3lq9s.png)
Dyslipidemia - StatPearls - NCBI Bookshelf
2024年3月4日 · Understanding the pathophysiology of dyslipidemia elucidates the role of a spectrum of interconnected metabolic and cardiovascular disturbances. Dyslipidemia can cause inflammation, oxidative stress, cardiovascular diseases, and other metabolic dysfunctions by different mechanisms, such as:
Pathophysiology of Dyslipidemia - an overview | ScienceDirect ...
This article discusses the pathophysiology of dyslipidemia in CKD, dialysis, and renal transplant patients, the therapeutic options, and their association with clinical outcomes. Whenever possible, comparisons are made to outcomes in the general population.
A Modern Approach to Dyslipidemia - PMC - PubMed Central …
We suggest a simplified overall approach to classification and management of patients with dyslipidemias: hypercholesterolemia, hypertriglyceridemia, combined dyslipidemia or other. Additional tests such as apo B and Lp (a) can help precisely stratify vascular disease risk.
Dyslipidemia - Endocrine and Metabolic Disorders - MSD Manual ...
Dyslipidemia is elevation of plasma cholesterol, triglycerides (TGs), or both, or a low high-density lipoprotein cholesterol (HDL-C) level that contributes to the development of atherosclerosis. Causes may be primary (genetic) or secondary. Diagnosis is by measuring plasma levels of total cholesterol, TGs, and individual lipoproteins.
Dyslipidemia and Cardiovascular Disease: Current Knowledge ...
Cardiovascular disease is the leading cause of morbidity and mortality worldwide, and dyslipidemia is one of the major risk factors. Hypercholesterolemia is the most common form of dyslipidemia [1].
Pathophysiology Dyslipidemia is associated with atherosclerosis in the procedure of causing cardiovascular disease. Cholesterol accumulated due to dyslipidemia is oxidized and accelerates the description of intercellular adhesion molecule (ICAM)-1 and endothelial selectin (E-selectin) for monocyte adhesion, thereupon
Pathophysiology, diagnosis, and management of dyslipidemia
It is critically important to recognize the need for treatment of dyslipidemia and to institute necessary therapies. The complex role of lipoprotein abnormalities is well understood and the use of lipid-lowering agents (90% statins) is reviewed in both primary and secondary prevention.